Prognostic role of copeptin after traumatic brain injury: A systematic review and meta-analysis of observational studies
- Authors
- Choi, Kyu Sun; Cho, Youngsuk; Jang, Bo-Hyoung; Kim, Wonhee; Ahn, Chiwon; Lim, Tae Ho; Yi, Hyeong Joong
- Issue Date
- Oct-2017
- Publisher
- W B SAUNDERS CO-ELSEVIER INC
- Keywords
- Traumatic brain injury; Copeptin; Meta-analysis; Prognosis
- Citation
- AMERICAN JOURNAL OF EMERGENCY MEDICINE, v.35, no.10, pp.1444 - 1450
- Indexed
- SCIE
SCOPUS
- Journal Title
- AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Volume
- 35
- Number
- 10
- Start Page
- 1444
- End Page
- 1450
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/151512
- DOI
- 10.1016/j.ajem.2017.04.038
- ISSN
- 0735-6757
- Abstract
- Purpose
Copeptin, the C-terminal portion of provasopressin, has emerged as a novel prognostic marker in neurocritical care, such as in traumatic brain injury (TBI). The aim of this study was to quantitatively assess the prognostic significance of initial plasma copeptin levels in the neurological outcome and mortality after traumatic brain injury.
Materials and methods
Six relevant studies with data from 552 patients were included in this meta-analysis.
Results
The plasma copeptin levels were found to be significantly higher in patients who died than in the survivors (standardized mean difference [SMD], 1.80). In the four studies reporting Glasgow outcome scale (GOS) data, patients with unfavorable outcomes had significantly higher copeptin levels than those with favorable outcomes (SMD, 1.62). The plasma copeptin level predicted mortality and unfavorable outcomes (AUC, 0.873; AUC, 0.876).
Conclusions
The present meta-analysis suggests that early measurement of plasma copeptin levels can provide better prognostic information about the functional outcome and mortality in patients with TBI.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 응급의학교실 > 1. Journal Articles
- 서울 의과대학 > 서울 신경외과학교실 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.